Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% | -.--% | -.--% |
Jul. 08 | Kymera Reports Expansion of KT-474 Trials; Shares Rise After-Hours | MT |
Jul. 08 | SANOFI : Jefferies maintains a Buy rating | ZD |
Business Summary
- pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases);
- human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas;
- consumer health products (12%).
At the end of 2023, the group had 54 production sites throughout the world.
Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biopharma
88.0
%
| 30,688 | 71.4 % | 37,890 | 88.0 % | +23.47% |
Consumer Healthcare
12.0
%
| 5,080 | 11.8 % | 5,180 | 12.0 % | +1.97% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
43.0
%
| 18,275 | 42.5 % | 18,512 | 43.0 % | +1.30% |
Rest of the World
26.1
%
| 8,386 | 19.5 % | 11,254 | 26.1 % | +34.20% |
Europe
18.6
%
| 7,703 | 17.9 % | 8,013 | 18.6 % | +4.02% |
China
6.8
%
| 3,123 | 7.3 % | 2,912 | 6.8 % | -6.76% |
France
5.5
%
| 2,296 | 5.3 % | 2,379 | 5.5 % | +3.61% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Paul Hudson
CEO | Chief Executive Officer | 56 | 19-08-31 |
Madeleine Roach
COO | Chief Operating Officer | 40 | 21-12-31 |
Chief Tech/Sci/R&D Officer | 51 | - | |
Nestle Frank
CTO | Chief Tech/Sci/R&D Officer | - | 16-08-31 |
Houman Ashrafian
CTO | Chief Tech/Sci/R&D Officer | 49 | 23-09-10 |
Dietmar Berger
CTO | Chief Tech/Sci/R&D Officer | - | 18-12-31 |
Arnaud Delépine
IRO | Public Communications Contact | - | - |
Raj Verma
PRN | Corporate Officer/Principal | - | 20-11-30 |
- | - | ||
Corporate Officer/Principal | 63 | 14-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick Kron
BRD | Director/Board Member | 70 | 14-04-30 |
Gilles Schnepp
BRD | Director/Board Member | 64 | 20-05-21 |
Frédéric Oudéa
CHM | Chairman | 61 | 22-09-01 |
Rachel Duan
BRD | Director/Board Member | 53 | 20-04-27 |
Antoine Yver
BRD | Director/Board Member | 66 | 22-05-02 |
Carole Ferrand
BRD | Director/Board Member | 53 | 22-05-02 |
Paul Hudson
CEO | Chief Executive Officer | 56 | 19-08-31 |
Emile Voest
BRD | Director/Board Member | 64 | 22-05-02 |
Yann Tran
BRD | Director/Board Member | 58 | 21-04-30 |
Wolfgang Laux
BRD | Director/Board Member | 56 | 21-03-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 1,264,799,969 | 1,102,029,493 ( 87.13 %) | 13,450,388 ( 1.063 %) | 87.13 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
SANOFI 1.28% | 16,245,648 | 1.28% | 1,565,969,997 $ |
SANOFI INDIA LIMITED 60.40% | 13,909,587 | 60.40% | 1,083,192,118 $ |
EUROAPI 29.60% | 28,298,074 | 29.60% | 77,337,504 $ |
MEIRAGTX HOLDINGS PLC 7.31% | 4,697,737 | 7.31% | 19,777,473 $ |
MEIRAGTX HOLDINGS PLC 8.00% | 1,157,926 | 8.00% | 16,407,811 $ |
LAVA THERAPEUTICS N.V. 7.30% | 1,919,455 | 7.30% | 3,455,019 $ |
ENENTO GROUP OYJ 0.12% | 29,249 | 0.12% | 514,101 $ |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Chattem, Inc.
Chattem, Inc. Pharmaceuticals: MajorHealth Technology Chattem, Inc. engages in the manufacture of over-the-counter health and beauty care products. It makes anti-dandruff shampoos, medicated skin care, topical pain care, oral care and internal over-the-counter products. The firm distributes its products to mass merchandisers, drugstores and food retail channels. The company was founded by Zeboim Cartter Patten on February 21, 1879 and is headquartered in Bridgewater, NJ. |
Pharmaceuticals: Major
|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. |
Medical Specialties
|
Bioverativ Therapeutics, Inc.
Bioverativ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bioverativ Therapeutics, Inc. develops pharmaceutical products. It develops medicines for chronic diseases such as hemophilia, anemia, multiple sclerosis, and autoimmune disorders. The company is headquartered in Cambridge, MA. |
Pharmaceuticals: Major
|
Aventis, Inc.
| |
Sanofi-Synthélabo Ltd.
Sanofi-Synthélabo Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sanofi-Synthélabo Ltd. is a pharmaceutical company based in Reading, UK. The British company was founded in 1990 and specializes in manufacturing and distributing solid-dose and pharmaceutical products. |
Pharmaceuticals: Major
|
Sanofi Pasteur, Inc.
Sanofi Pasteur, Inc. Pharmaceuticals: MajorHealth Technology Sanofi Pasteur, Inc. provides vaccines for the prevention and treatment of diseases. It develops and manufactures influenza vaccine against the pandemic influenza virus. The company was founded in 1897 and is headquartered in Swiftwater, PA. |
Pharmaceuticals: Major
|
Sanofi-aventis Ireland Ltd.
Sanofi-aventis Ireland Ltd. Pharmaceuticals: MajorHealth Technology Sanofi-aventis Ireland Ltd. manufactures pharmaceutical products for cardiovascular, central nervous system, metabolic disorders, cardiometabolic, oncology, thrombosis, and vaccines. The company is headquartered in Dublin, Ireland. |
Pharmaceuticals: Major
|
Sanofi-Aventis Europe SAS
Sanofi-Aventis Europe SAS Pharmaceuticals: MajorHealth Technology Part of Sanofi, Sanofi-Aventis Europe SAS is a pharmaceutical company based in Paris, France. The French company manufactures pharmaceuticals. The CEO of the company is Jérôme Contamine. |
Pharmaceuticals: Major
|
Genzyme Therapeutic Products LP
Genzyme Therapeutic Products LP BiotechnologyHealth Technology Part of Sanofi, Genzyme Therapeutic Products LP is a company that specializes in biological products except diagnostic substances. The company is based in Boston, MA. |
Biotechnology
|
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+57.48% | 823B | |
-7.18% | 353B | |
+15.37% | 320B | |
+7.45% | 295B | |
+13.62% | 239B | |
+14.55% | 220B | |
-0.33% | 219B | |
+8.14% | 167B | |
-2.99% | 159B |
- Stock Market
- Equities
- SAN Stock
- 0O59 Stock
- Company Sanofi